Similarly, in a randomized placebo-controlled clinical trial, mRNA levels of ASC and NLRP3 were not significantly lower in peripheral blood mononuclear cells (PBMCs) from patients with nonalcoholic fatty liver disease (NAFLD), compared to the control group, after 12 weeks of anthocyanin supplementation [42]. Here, NLRP3 is linked to metabolic dysfunction-associated steatotic liver disease.